Tumor downstaging in muscle invasive bladder cancer with neoadjuvant systemic therapy—does it lead to prolonged survival?
| dc.contributor.author | Tachibana, Isamu | |
| dc.contributor.author | Kaimakliotis, Hristos Z. | |
| dc.contributor.department | Urology, School of Medicine | en_US |
| dc.date.accessioned | 2020-07-30T22:11:51Z | |
| dc.date.available | 2020-07-30T22:11:51Z | |
| dc.date.issued | 2020-04 | |
| dc.eprint.version | Final published version | en_US |
| dc.identifier.citation | Tachibana, I., & Kaimakliotis, H. Z. (2020). Tumor downstaging in muscle invasive bladder cancer with neoadjuvant systemic therapy-does it lead to prolonged survival?. Translational andrology and urology, 9(2), 831–833. https://doi.org/10.21037/tau.2019.12.28 | en_US |
| dc.identifier.uri | https://hdl.handle.net/1805/23464 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | AME Publishing Company | en_US |
| dc.relation.isversionof | 10.21037/tau.2019.12.28 | en_US |
| dc.relation.journal | Translational Andrology and Urology | en_US |
| dc.rights | Publisher Policy | en_US |
| dc.source | PMC | en_US |
| dc.subject | Tumor downstaging | en_US |
| dc.subject | Muscle invasive bladder cancer | en_US |
| dc.subject | Neoadjuvant systemic therapy | en_US |
| dc.subject | Complete clinical response | en_US |
| dc.subject | Improved overall survival | en_US |
| dc.title | Tumor downstaging in muscle invasive bladder cancer with neoadjuvant systemic therapy—does it lead to prolonged survival? | en_US |
| dc.type | Article | en_US |
| ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215006/ | en_US |